Bardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageBardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageMoxonidine is a new-generation centrally-acting antihypertensive drug. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction.
More Information Supplier PageA 740003 is a novel competitive antagonist of P2X7 receptors (IC50 values = 40 nM for human and 18 nM for rat).
More Information Supplier PageA 740003 is a novel competitive antagonist of P2X7 receptors (IC50 values = 40 nM for human and 18 nM for rat).
More Information Supplier PageA 740003 is a novel competitive antagonist of P2X7 receptors (IC50 values = 40 nM for human and 18 nM for rat).
More Information Supplier PageA 740003 is a novel competitive antagonist of P2X7 receptors (IC50 values = 40 nM for human and 18 nM for rat).
More Information Supplier Page
